Home > Newsletters > Drug Industry Daily > Sponsors Resigned to Trials for Biosimilar Interchangeability, May Limit Pipelines
Drug Industry Daily
Sept. 17, 2012 | Vol. 11 No. 182
Sponsors Resigned to Trials for Biosimilar Interchangeability, May Limit Pipelines
The FDA appears poised to require clinical trial data from drugmakers seeking biosimilar interchangeability designations, a move that could shrink the number of products that aim to achieve the standard, drugmakers and legal experts say.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.